Bodenhoff Mads sold $811K of ASND

Ascendis Pharma (ASND) authorized a $400M share buyback. Q2 2025 saw €315M product revenue, up 105% YoY, with €220M operating profit. Cash reserves grew to €812M. Buyback is discretionary, dependent on market conditions. YORVIPATH drove most revenue, while SKYTROFA and YUVIWEL contributed less. Costs increased due to expansion and R&D.

Ascendis Pharma (ASND) and BioMarin (BMRN) settled a patent dispute, with ASND paying BMRN royalties on Yuviwel sales. ASND rose 6% and BMRN 1%. Analysts adjusted targets but kept ratings unchanged, citing legal clarity and growth prospects.

Ascendis Pharma (ASND) fell 13% to $230.28 after authorizing a $400M share repurchase program. The stock traded between $230.18 and $257.53 with high volume. Repurchases may occur via various methods, subject to market conditions. The 52-week range is $186.05 to $282.15.

Ascendis Pharma (ASND) fell 10.9% after ending a metabolic and cardiovascular collaboration, reverting rights to TransCon semaglutide. Analysts downgraded the stock, despite a $400M share buyback plan. Investors may be reassessing the program's value and development path.

Ascendis Pharma (ASND) will regain full rights to its TransCon metabolic and cardiovascular programs, including obesity treatments, after ending its collaboration with Novo Nordisk. The termination, effective September 14, 2026, returns all licenses to Ascendis without ongoing financial obligations. This move may impact the company's strategic options and market positioning, though it also introduces development and regulatory risks.

Ascendis Pharma (ASND) announced a $400M share repurchase program on September 14, 2026. The buyback may occur through open-market purchases or structured transactions, with flexibility to adjust or terminate. Execution depends on market conditions, share price, and other factors, with potential impact on earnings per share and stock price, though broader risks remain.